Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

Launched by UNIVERSITY OF HAWAII · Apr 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called tirzepatide on weight loss and inflammation in adults who are overweight or obese and living with well-controlled HIV. The trial aims to see how this medication can help reduce body weight and improve certain health markers related to inflammation and heart health over 12 weeks. Participants will start with a low dose of tirzepatide, which will be gradually increased, and their progress will be monitored throughout the study.

To be eligible for this trial, individuals must be at least 18 years old, have a well-controlled HIV infection, and meet specific weight criteria (either being overweight with related health issues or being obese). They should also have been on stable HIV treatment for at least a year. During the trial, participants can expect to receive weekly doses of the medication, and their health will be checked regularly to assess any changes in weight and inflammation. After the treatment period, there will be an additional follow-up to ensure safety. This study is not yet recruiting participants, but it offers a potential opportunity for those who qualify to contribute to important research in this area.

Gender

ALL

Eligibility criteria

• • Age ≥ 18 years
• • HIV-1 infection (well controlled)
• • Documented HIV-1 infection ≥ 1 year prior to study entry (ELISA confirmed by Western blot or HIV-1 RNA) AND
• • HIV-1 RNA \<200 copies/mL for ≥ 6 months
• • Stable ART
• • · Receiving a stable antiretroviral regimen for at least 1 year prior to study entry
• • Overweight
• • BMI ≥27 kg/m2 plus at least one weight-related condition (defined as a medical history of dyslipidemia, hypertension, cardiovascular disease, or obstructive sleep apnea) OR Obese
• • BMI ≥ 30 kg/m2